Health Care & Life Sciences » Pharmaceuticals | Taiko Pharmaceutical Co. Ltd.

Taiko Pharmaceutical Co. Ltd. | Income Statement

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Sales/Revenue
9,947
9,238
8,295
8,285
9,438
10,378
Cost of Goods Sold (COGS) incl. D&A
2,684
2,355
2,556
2,714
2,886
3,216
Gross Income
7,264
6,883
5,739
5,571
6,552
7,162
SG&A Expense
4,594
4,324
4,391
4,025
4,695
5,132
EBIT
2,591
2,559
1,348
1,545
1,857
2,030
Unusual Expense
126
61
216
85
19
123
Non Operating Income/Expense
84
253
59
141
325
75
Interest Expense
-
-
3
-
-
-
Pretax Income
2,554
2,759
1,192
1,491
1,553
1,986
Income Tax
806
988
351
442
458
570
Consolidated Net Income
1,747
1,771
840
1,049
1,095
1,415
Net Income
1,747
1,771
840
1,049
1,095
1,415
Net Income After Extraordinaries
1,747
1,771
840
1,049
1,095
1,415
Net Income Available to Common
1,747
1,771
840
1,049
1,095
1,415
EPS (Basic)
135.94
138.94
65.23
76.45
77.39
99
Basic Shares Outstanding
13
13
13
14
14
14
EPS (Diluted)
131.57
134.49
63.83
75.82
77.07
98.89
Diluted Shares Outstanding
13
13
13
14
14
14
EBITDA
2,849
2,840
1,698
1,990
2,311
2,491
Other Operating Expense
79
-
-
-
-
-
Non-Operating Interest Income
4
7
4
2
1
4

About Taiko Pharmaceutical Co.

View Profile
Address
ORIX Honmachi Building, 16F
Osaka Osaka 550
Japan
Employees -
Website http://www.seirogan.co.jp
Updated 07/08/2019
Taiko Pharmaceutical Co., Ltd. engages in the manufacture and sale of general medications particularly non-prescription gastrointestinal drugs and designated quasi drugs, and sanitation control products. It operates through the following segments: Pharmaceuticals, Infection Control, and Others. The Pharmaceuticals segment handles the manufacture, procurement and sale of non-prescription (OTC) drugs in Japan and overseas.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.